

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPAL600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 JAN 12 Match STN Content and Features to Your Information  
Needs, Quickly and Conveniently  
NEWS 3 JAN 25 Annual Reload of MEDLINE database  
NEWS 4 FEB 16 STN Express Maintenance Release, Version 8.4.2, Is  
Now Available for Download  
NEWS 5 FEB 16 Derwent World Patents Index (DWPI) Revises Indexing  
of Author Abstracts  
NEWS 6 FEB 16 New FASTA Display Formats Added to USGENE and PCTGEN  
NEWS 7 FEB 16 INPADOCDB and INPAFAMDB Enriched with New Content  
and Features  
NEWS 8 FEB 16 INSPEC Adding Its Own IPC codes and Author's E-mail  
Addresses  
NEWS 9 APR 02 CAS Registry Number Crossover Limits Increased to  
500,000 in Key STN Databases  
NEWS 10 APR 02 PATDPAFULL: Application and priority number formats  
enhanced  
NEWS 11 APR 02 DWPI: New display format ALLSTR available  
NEWS 12 APR 02 New Thesaurus Added to Derwent Databases for Smooth  
Sailing through U.S. Patent Codes  
NEWS 13 APR 02 EMBASE Adds Unique Records from MEDLINE, Expanding  
Coverage back to 1948  
NEWS 14 APR 07 CA/CAPLUS CLASS Display Streamlined with Removal of  
Pre-IPC 8 Data Fields  
NEWS 15 APR 07 50,000 World Traditional Medicine (WTM) Patents Now  
Available in CAPLUS  
NEWS 16 APR 07 MEDLINE Coverage Is Extended Back to 1947  
NEWS 17 JUN 16 WPI First View (File WPIFV) will no longer be  
available after July 30, 2010  
NEWS 18 JUN 18 DWPI: New coverage - French Granted Patents  
NEWS 19 JUN 18 CAS and FIZ Karlsruhe announce plans for a new  
STN platform  
NEWS 20 JUN 18 IPC codes have been added to the INSPEC backfile  
(1969-2009)  
NEWS 21 JUN 21 Removal of Pre-IPC 8 data fields streamline displays  
in CA/CAPLUS, CASREACT, and MARPAT  
NEWS 22 JUN 21 Access an additional 1.8 million records exclusively  
enhanced with 1.9 million CAS Registry Numbers --  
EMBASE Classic on STN  
NEWS 23 JUN 28 Introducing "CAS Chemistry Research Report": 40 Years  
of Biofuel Research Reveal China Now Atop U.S. in  
Patenting and Commercialization of Bioethanol  
NEWS 24 JUN 29 Enhanced Batch Search Options in DGENE, USGENE,  
and PCTGEN

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,

AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS      STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN      Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:42:54 ON 08 JUL 2010

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 10:43:06 ON 08 JUL 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES:    7 JUL 2010    HIGHEST RN 1229513-84-1

DICTIONARY FILE UPDATES:   7 JUL 2010    HIGHEST RN 1229513-84-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10590845.str



```

chain nodes :
10 17
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 18 19 20 21 22 23
chain bonds :
9-10 10-11 17-18
ring bonds :
1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16 18-19 18-23 19-20 20-21 21-22 22-23
exact/norm bonds :
1-7 2-9 7-8 8-9 9-10 17-18 18-19 18-23 19-20 20-21 21-22 22-23
exact bonds :
10-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16

```

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS

```

L1 STRUCTURE UPLOADED

```

=> d
L1 HAS NO ANSWERS
L1 STR

```

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

```

=> s l1
SAMPLE SEARCH INITIATED 10:43:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      974 TO ITERATE

100.0% PROCESSED      974 ITERATIONS                5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   17608 TO    21352
PROJECTED ANSWERS:      5 TO      234

L2                5 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 10:43:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    19206 TO ITERATE

100.0% PROCESSED    19206 ITERATIONS                90 ANSWERS
SEARCH TIME: 00.00.01

L3                90 SEA SSS FUL L1

=> s l3 and caplus/lc
      71340420 CAPLUS/LC
L4                87 L3 AND CAPLUS/LC


=> s l3 not l4
L5                3 L3 NOT L4

=> d l5 1-3

```

L5 ANWER 1 OF 3 REGISTRY COPYRIGHT 2010 ACS on STN  
 RN 864172-41-4 REGISTRY  
 ED Entered STN: 29 Sep 2005  
 CN 4-Morpholinemethanamine, N-[[[cis-4-[[4-[[2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl)methyl]- (CA INDEX NAME)  
 TS STEREOSEARCH  
 MF C29 842 86 0  
 CI C08  
 SR CA


Relative stereochemistry:



\*\*PROPERTY DATA AVAILABLE IN THE 'PROF' FORMAT\*\*


L5 ANWER 2 OF 3 REGISTRY COPYRIGHT 2010 ACS on STN  
 RN 864173-77-7 REGISTRY  
 ED Entered STN: 29 Sep 2005  
 CN 1-Pyrrolidinemethanamine, N-[[[trans-4-[[4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl)methyl]- (CA INDEX NAME)  
 TS STEREOSEARCH  
 MF C29 844 86  
 CI C08  
 SR CA

Relative stereochemistry:



\*\*PROPERTY DATA AVAILABLE IN THE 'PROF' FORMAT\*\*

L5 ANWER 3 OF 3 REGISTRY COPYRIGHT 2010 ACS on STN  
 RN 864172-59-5 REGISTRY  
 ED Entered STN: 29 Sep 2005  
 CN Benzenesulfonamide, 4-[[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[4-[[4-methyl-2-piperazinyl)methyl]phenyl]- (CA INDEX NAME)  
 MF C29 826 86  
 CI C08  
 SR CA



\*\*PROPERTY DATA AVAILABLE IN THE 'PROF' FORMAT\*\*

=> fil caplus  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
203.34	203.56

FILE 'CAPLUS' ENTERED AT 10:43:53 ON 08 JUL 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Jul 2010 VOL 153 ISS 2  
FILE LAST UPDATED: 7 Jul 2010 (20100707/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2010  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2010

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

16 ANSWER 1 OF 4 CAPLOS COPYRIGHT 2010 ACS ON STM  
 ACCESSION NUMBER: 2007028184 CAPLOS

DOCUMENT NUMBER: 14609933

TITLE:

Preventives and/or remedies for X-ray induced lung injury containing GPR4 signaling inhibitors

INVENTOR(S): Ruter, Masahiko Hsu, Genya; Ohama, Kenzo; Minabe, Haruhiko; Watanabe, Akihiko

PATENT ASSIGNER(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 47pp.

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007028184	A	20070115	JP 2006-207043	20060731
PRIORITY APPL. INFO.			JP 2005-223037	A 20050901

OTHER SOURCE(S): MEDPARK 146099333

AB The invention provides a preventive and/or remedy for X-ray induced lung injury characterized by containing a compound which inhibits signal transduction of GPR4 (G protein-coupled receptor 4), including an azetidine as oligopeptide, antibody, and imidazopyridine derivative

For example, a compound 2-[2-ethyl-5,7-dimethyl-3H-indazo[4,5-b]pyridin-3-ylmethyl]-8-[4-methylpiperazin-1-ylmethyl]-3,11-di-ethoxylo, flosapone difumarate was prepared, and examined for its GPR4 antagonistic effect

and TGF- $\alpha$  production inhibitory effect in vitro.


IT 927822-02-2P 927822-02-4P 927822-04-4P

927822-05-7P Rls NCT (Reactant); GPR (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

Preparation of preventives and/or remedies for X-ray induced lung injury containing GPR4 signaling inhibitors)

927822-02-3 CAPLOS

CH Methanone, [4-[[[2-ethyl-5,7-dimethyl-3H-indazo[4,5-b]pyridin-3-ylmethyl]phenyl]amino]cyclohexyl] (4-methyl-1-piperazinyl)- (CA INDEX NAME)



927822-02-4 CAPLOS

CH Cyclohexanecarboxylic acid, 4-[[[2-ethyl-5,7-dimethyl-3H-indazo[4,5-b]pyridin-3-ylmethyl]phenyl]amino]-, ethyl ester (CA INDEX NAME)

16 ANSWER 1 OF 4 CAPLOS COPYRIGHT 2010 ACS ON STM (Continued)


75(specific use); BCL (Biological study); PREP (Preparation); USES (Uses)

Preventives and/or remedies for X-ray induced lung injury contg. GPR4 signaling inhibitors)

927822-04-4 CAPLOS

CH Benzotriazole, 4-[[[2-ethyl-5,7-dimethyl-3H-indazo[4,5-b]pyridin-3-ylmethyl]-N-(4-[[[4-methyl-1-piperazinyl]methyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



927822-39-3 CAPLOS

CH Benzotriazole, 4-[[[2-ethyl-5,7-dimethyl-3H-indazo[4,5-b]pyridin-3-ylmethyl]-N-(4-[[[4-methyl-1-piperazinyl]methyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



16 ANSWER 1 OF 4 CAPLOS COPYRIGHT 2010 ACS ON STM (Continued)

ACCESSION NUMBER: 2007123775 CAPLOS

DOCUMENT NUMBER: 146266782

TITLE:

Chemokine production inhibitors

INVENTOR(S): Sakai, Mayumi; Nara, Kazuya; Sasaki, Katsutoshi

PATENT ASSIGNER(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: PCT Int. Appl., 67pp.

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007023800	A1	20070301	WO 2006-073160	20060814

927822-04-4 CAPLOS


CH Cyclohexanecarboxylic acid, 4-[[[2-ethyl-5,7-dimethyl-3H-indazo[4,5-b]pyridin-3-ylmethyl]phenyl]amino]cyclohexyl] (4-methyl-1-piperazinyl)-, ethanediolate (1:1) (CA INDEX NAME)



CH 1

927822-00-2

CHF C29 B49 NC O



CH 2

144-62-7

CHF C2 H2 O4

NO<sub>2</sub> C=O

CH 2

144-62-7

CHF C2 H2 O4

NO<sub>2</sub> C=O

CH 2

144-62-7

CHF C2 H2 O4

NO<sub>2</sub> C=O

CH 2

144-62-7

CHF C2 H2 O4

NO<sub>2</sub> C=O

CH 2

144-62-7

CHF C2 H2 O4

NO<sub>2</sub> C=O

CH 2

144-62-7

CHF C2 H2 O4

NO<sub>2</sub> C=O

CH 2

144-62-7

CHF C2 H2 O4

NO<sub>2</sub> C=O

CH 2

144-62-7

CHF C2 H2 O4

NO<sub>2</sub> C=O

CH 2

144-62-7

CHF C2 H2 O4

NO<sub>2</sub> C=O

CH 2

144-62-7

CHF C2 H2 O4

NO<sub>2</sub> C=O

CH 2

144-62-7

CHF C2 H2 O4

NO<sub>2</sub> C=O

CH 2

144-62-7

CHF C2 H2 O4

NO<sub>2</sub> C=O

CH 2

144-62-7

CHF C2 H2 O4

NO<sub>2</sub> C=O

CH 2

144-62-7

CHF C2 H2 O4

NO<sub>2</sub> C=O

CH 2

144-62-7

CHF C2 H2 O4

NO<sub>2</sub> C=O

CH 2

144-62-7

CHF C2 H2 O4

NO<sub>2</sub> C=O

CH 2

144-62-7

CHF C2 H2 O4

NO<sub>2</sub> C=O

CH 2

PRIORITY APPL. INFO.: JP 2005-242394 A 20050814

OTHER SOURCE(S): MEDPARK 146266782


GI

AB Disclosed are a chemokine production inhibitor comprising a substance capable

of inhibiting the function involved in signal transduction of GPR4 as an active ingredient; a chemokine production inhibitor comprising a nitrogenated

tricyclic compound represented by the formula I (R1 represents a (un)substituted heterocyclic group, R2aR2b where R2a and R2b independently represent R, a (un)substituted lower alkyl group or the like; R2 represents a H or the like; R3 and R4 independently represent a H or the like; X represents -CH2CH2- or the like; and Y represents the formula II where Z represents CH or N; R5a and R5b independently represent R, a (un)substituted lower alkyl group or the like; and R2 represents a H or the like; or a pharmaceutically acceptable salt thereof as an active ingredient; and others.

The chemokine production inhibitor includes antisense oligonucleotide and



AB Disclosed are a chemokine production inhibitor comprising a substance capable

of inhibiting the function involved in signal transduction of GPR4 as an active ingredient; a chemokine production inhibitor comprising a nitrogenated

tricyclic compound represented by the formula I (R1 represents a (un)substituted heterocyclic group, R2aR2b where R2a and R2b independently represent R, a (un)substituted lower alkyl group or the like; R2 represents a H or the like; R3 and R4 independently represent a H or the like; X represents -CH2CH2- or the like; and Y represents the formula II where Z represents CH or N; R5a and R5b independently represent R, a (un)substituted lower alkyl group or the like; and R2 represents a H or the like; or a pharmaceutically acceptable salt thereof as an active ingredient; and others.

The chemokine production inhibitor includes antisense oligonucleotide and

AB Disclosed are a chemokine production inhibitor comprising a substance capable

of inhibiting the function involved in signal transduction of GPR4 as an active ingredient; a chemokine production inhibitor comprising a nitrogenated

tricyclic compound represented by the formula I (R1 represents a (un)substituted heterocyclic group, R2aR2b where R2a and R2b independently represent R, a (un)substituted lower alkyl group or the like; R2 represents a H or the like; R3 and R4 independently represent a H or the like; X represents -CH2CH2- or the like; and Y represents the formula II where Z represents CH or N; R5a and R5b independently represent R, a (un)substituted lower alkyl group or the like; and R2 represents a H or the like; or a pharmaceutically acceptable salt thereof as an active ingredient; and others.

The chemokine production inhibitor includes antisense oligonucleotide and

AB Disclosed are a chemokine production inhibitor comprising a substance capable

```


L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
   GPR4 signal transduction)
FN 864172-71-4 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-
  b]pyridin-3-yl)methyl]phenyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.

```

IT 064173-83-SP 064173-86-SP  
 ELI PAC (Pharmacological activity); GPI (Synthetic preparation); TEO  
 (Therapeutic use); BIO (Biological study); PREP (Preparation); USES  
 (Uses)  
 Chemokine production inhibitor comprising substances capable of  
 inhibiting GPR4 signal transduction)  
 J20 064173-83-5 CAS/US  
 C21 Methanone, [4-methyl-1-piperazinyl][trans-4-[[-[2,5,7-trimethyl-3H-  
 imidazo[4,5-b]pyridin-2-yl)methyl]phenyl]amino)cyclohexyl]- (CA 126XK  
 NMS)

Relative stereochemistry.




```

920  IN4171-86-8  CAPLOS
CN    Cyclohexanecarboxamide, N-[2-[1-pyrrolidinyl)ethyl]-4-[[4-[[2,5,7-
      trimethyl-2H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino], trans-
ICA   INDEX NAME)

```

Relative stereochemistry.




27 864172-71-4P  
RL: RCT (Reactant); SPM (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
phenokine production inhibitor comprising substances capable of  
inhibiting

16 ARJISER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STM  
ACCESSION NUMBER: 2005:979653 CAPLUS  
ACCESSION NUMBER: 443-200-100

DOCUMENT NUMBER: 141286426  
 PREPARATION: Preparation of imidazo[5,4-b]pyridine derivatives as  
 TITLE: GPR4 receptor antagonists for treatment of  
 neutrophilic inflammation  
 INVENTOR(S): Iida, Yoshiyoshi; Grube, Shunmasa; Tsuboyama, Takeshi;  
 Arai, Hiroshi; Watanabe, Akiko; Sakai, Mayumi  
 ELISA: Masuo Masuo; Banburoki Takada, Hiroyuki; Saito, Jun  
 PATENT ASSIGNEE(S): FUJIFILM KASEI CO., LTD., Japan  
 SOURCE: PCT Int. Appl., 178 pp.  
 COUNTRY: PCT/JP2002/000222  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1


[illegible]

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LEXUS DISPLAY FORMAT  
OTHER SOURCE(S): MARPAT 143:286426  
BT




IT 064172-28-1P  
KL: SYN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(chemokine production inhibitor comprising substances capable of inhibiting

GPR4 signal transduction)  
 IN 04172-28-1 CAPSUS  
 CN Cyclohexanecarboxylic acid, 4-[[4-[[2,5,7-trimethyl-3H-imidazo[4,5-  
 b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester, trans- ICA INDE  
 NAME)  
 Relative stereochemistry.




REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

16 ANSWER 3 OF 4 CAPLOS COPYRIGHT 2010 ACS on STN (Continued)















<sup>1</sup>A2 The title compds. I [wherein R1 = H, halo, CN, etc.; A1-A2-A3-A4 = (un)substituted CH=CH-C≡CH, CH=CH-CH=CH, CH=CH-CH=CH, CH=CH-CH=CH, CH=CH-CH=CH, N=CH-N=CH, C≡C-N≡C, or N=C-CH=N, or N=C-CH=N, Q = (un)substituted phenylene, naphthylene, heterocylene, etc.; T = C≡O, (un)substituted alkyl, cycloalkyl, etc.] or pharmaceutically acceptable salts thereof are prepared as G protein-coupled receptor (GPCR) antagonists for the treatment

1a	of neutrophilic inflammation. For example, the compound II was prepared as a multi-step synthesis. II inhibited 75% of human GPR4 at the concentration of 100 nM.			
37	$\mu$ M			
	0.6171-55-29	0.6171-57-39	0.6171-61-39	
	0.6171-65-29	0.6171-67-59	0.6171-68-49	
	0.6171-70-29	0.6171-71-59	0.6171-72-49	
	0.6171-76-49	0.6171-79-09	0.6171-81-39	
	0.6171-83-29	0.6171-84-59	0.6171-85-49	
	0.6171-92-09	0.6171-93-29	0.6171-94-39	
	0.6171-97-09	0.6171-97-29	0.6171-98-39	
	0.6171-99-09	0.6171-99-29	0.6171-99-39	
	0.6171-99-49	0.6171-99-59	0.6171-99-69	
	0.6171-99-79	0.6171-99-89	0.6171-99-99	
	0.6171-99-09	0.6171-99-19	0.6171-99-29	
	0.6171-99-39	0.6171-99-49	0.6171-99-59	
	0.6171-99-69	0.6171-99-79	0.6171-99-89	
	0.6171-99-99	0.6171-99-09	0.6171-99-19	
	0.6171-99-29	0.6171-99-39	0.6171-99-49	
	0.6171-99-59	0.6171-99-69	0.6171-99-79	
	0.6171-99-89	0.6171-99-99	0.6171-99-09	
	0.6171-99-19	0.6171-99-29	0.6171-99-39	
	0.6171-99-49	0.6171-99-59	0.6171-99-69	
	0.6171-99-79	0.6171-99-89	0.6171-99-99	
	0.6171-99-09	0.6171-99-19	0.6171-99-29	
	0.6171-99-39	0.6171-99-49	0.6171-99-59	
	0.6171-99-69	0.6171-99-79	0.6171-99-89	
	0.6171-99-99	0.6171-99-09	0.6171-99-19	
	0.6171-99-29	0.6171-99-39	0.6171-99-49	
	0.6171-99-59	0.6171-99-69	0.6171-99-79	
	0.6171-99-89	0.6171-99-99	0.6171-99-09	
	0.6171-99-19	0.6171-99-29	0.6171-99-39	
	0.6171-99-49	0.6171-99-59	0.6171-99-69	
	0.6171-99-79	0.6171-99-89	0.6171-99-99	
	0.6171-99-09	0.6171-99-19	0.6171-99-29	
	0.6171-99-39	0.6171-99-49	0.6171-99-59	
	0.6171-99-69	0.6171-99-79	0.6171-99-89	
	0.6171-99-99	0.6171-99-09	0.6171-99-19	
	0.6171-99-29	0.6171-99-39	0.6171-99-49	
	0.6171-99-59	0.6171-99-69	0.6171-99-79	
	0.6171-99-89	0.6171-99-99	0.6171-99-09	
	0.6171-99-19	0.6171-99-29	0.6171-99-39	
	0.6171-99-49	0.6171-99-59	0.6171-99-69	
	0.6171-99-79	0.6171-99-89	0.6171-99-99	
	0.6171-99-09	0.6171-99-19	0.6171-99-29	
	0.6171-99-39	0.6171-99-49	0.6171-99-59	
	0.6171-99-69	0.6171-99-79	0.6171-99-89	
	0.6171-99-99	0.6171-99-09	0.6171-99-19	
	0.6171-99-29	0.6171-99-39	0.6171-99-49	
	0.6171-99-59	0.6171-99-69	0.6171-99-79	
	0.6171-99-89	0.6171-99-99	0.6171-99-09	
	0.6171-99-19	0.6171-99-29	0.6171-99-39	
	0.6171-99-49	0.6171-99-59	0.6171-99-69	
	0.6171-99-79	0.6171-99-89	0.6171-99-99	
	0.6171-99-09	0.6171-99-19	0.6171-99-29	
	0.6171-99-39	0.6171-99-49	0.6171-99-59	
	0.6171-99-69	0.6171-99-79	0.6171-99-89	
	0.6171-99-99	0.6171-99-09	0.6171-99-19	
	0.6171-99-29	0.6171-99-39	0.6171-99-49	
	0.6171-99-59	0.6171-99-69	0.6171-99-79	
	0.6171-99-89	0.6171-99-99	0.6171-99-09	
	0.6171-99-19	0.6171-99-29	0.6171-99-39	
	0.6171-99-49	0.6171-99-59	0.6171-99-69	
	0.6171-99-79	0.6171-99-89	0.6171-99-99	
	0.6171-99-09	0.6171-99-19	0.6171-99-29	</




Q2 Methanone, [4-[[4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]phenyl][4-methyl-3-piperazinyl]- ICA INDEX NAME






16 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 CN Cyclohexanecarboxamide, 4-[[4-[[2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-N-[2-(4-morpholinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




ZN 864171-84-8 CAPLUS  
 CN Cyclohexanecarboxamide, 4-[[4-[[2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-N-[2-(4-morpholinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




ZN 864172-07-6 CAPLUS  
 CN 1,4-Dioxaspiro[4.5]decan-8-amine, N-[[4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)

16 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



ZN 864172-39-5 CAPLUS  
 CN Cyclohexanecarboxylic acid, 4-[[4-[[2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester, trans- (CA INDEX NAME)


Relative stereochemistry.




ZN 864172-31-6 CAPLUS  
 CN Cyclohexanecarboxylic acid, 4-[[4-[[2-(2-furanyl)-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.

16 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




Relative stereochemistry.



ZN 864172-29-1 CAPLUS  
 CN Cyclohexanecarboxylic acid, 4-[[4-[[2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester, trans- (CA INDEX NAME)


Relative stereochemistry.



ZN 864172-23-2 CAPLUS  
 CN Cyclohexanecarboxylic acid, 4-[[4-[[2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester, trans- (CA INDEX NAME)


Relative stereochemistry.

16 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




ZN 864172-35-0 CAPLUS  
 CN Cyclohexanecarboxylic acid, 4-[[4-[[5-chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.




ZN 864172-72-2 CAPLUS  
 CN Methanone, [cis-4-[[4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]-(4-methyl-3-piperidinyl)- (CA INDEX NAME)


Relative stereochemistry.




RU 864172-29-4 CAPLUS  
 CN Methanone, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl-1-morpholinyl-1- (CA INDEX NAME)  
 Relative stereochemistry.



RU 864172-40-7 CAPLUS  
 CN Methanone, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl-1-pyrrolidinyl-1- (CA INDEX NAME)  
 Relative stereochemistry.




RU 864172-44-1 CAPLUS  
 CN Methanone, 4-methyl-1-piperazinyl[[4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]-1- (CA INDEX NAME)  
 Relative stereochemistry.




RU 864172-51-0 CAPLUS  
 CN Methanone, 4-morpholinyl[[4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]-1- (CA INDEX NAME)  
 Relative stereochemistry.



RU 864171-55-1 CAPLUS  
 CN Benzenamine, 3-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-phenyl- (CA INDEX NAME)  
 Relative stereochemistry.




RU 864171-58-4 CAPLUS  
 CN Benzenethanol, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)  
 Relative stereochemistry.



RU 864171-60-8 CAPLUS  
 CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-1,2,4-triazole-5-yl]- (CA INDEX NAME)  
 CN 1  
 CN 864171-59-5  
 CN 864171-59-5  
 CN 864171-59-5



RU 864172-53-2 CAPLUS  
 CN Methanone, 4-[[4-hydroxymethyl]-5-piperidinyl][[4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]-1- (CA INDEX NAME)  
 Relative stereochemistry.



RU 864171-54-0P 864171-55-1P 864171-58-4P  
 864171-60-8P 864172-62-2P 864171-66-4P  
 864171-69-7P 864171-70-0P 864171-73-7P  
 864171-75-5P 864171-76-0P 864171-80-2P  
 864171-86-8P 864171-87-9P 864171-88-0P  
 864171-89-1P 864172-91-5P 864171-92-0P  
 864171-93-7P 864171-95-0P 864171-96-0P  
 864171-97-1P 864172-10-1P 864172-21-4P  
 864172-22-5P 864172-32-7P 864172-33-9P  
 864172-34-9P 864172-36-1P 864172-38-7P  
 864172-42-9P 864172-43-0P 864172-45-2P  
 864172-46-3P 864172-48-5P 864172-49-4P  
 864172-50-9P 864172-52-1P 864172-54-7P


RU 864171-54-0 CAPLUS  
 CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-phenyl- (CA INDEX NAME)  
 Relative stereochemistry.

RU 864171-54-0 CAPLUS  
 CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-phenyl- (CA INDEX NAME)  
 Relative stereochemistry.


RU 864171-54-0 CAPLUS  
 CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-phenyl- (CA INDEX NAME)  
 Relative stereochemistry.




RU 864171-62-0 CAPLUS  
 CN Benzenamine, N-cyclohexyl-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)  
 Relative stereochemistry.



RU 864171-66-4 CAPLUS  
 CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[[4-[(4-methyl-1-piperazinyl)methyl]cyclohexyl]-1- (CA INDEX NAME)  
 Relative stereochemistry.




RU 864171-69-7 CAPLUS  
 CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[[4-[(4-methyl-1-piperazinyl)methyl]cyclohexyl]-1- (CA INDEX NAME)  
 Relative stereochemistry.



RU 864171-70-0 CAPLUS  
 CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[[4-[(4-methyl-1-piperazinyl)methyl]cyclohexyl]-1- (CA INDEX NAME)  
 Relative stereochemistry.






RU 864171-73-3 CAPLOS

CN Benzenamine, 4-[[2-ethyl-5,7-dimethyl-3H-indolo[4,5-b]pyridin-3-yl)methyl]-N-[[trans-4-[[4-[[2-ethyl-5,7-dimethyl-3H-indolo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)


Relative stereochemistry.



RU 864171-75-5 CAPLOS

CN 4-Piperidinecarboxamide, 1-[[trans-4-[[4-[[2-ethyl-5,7-dimethyl-3H-indolo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RU 864171-79-8 CAPLOS

CN 1-Pyrrolidinecarboxamide, N-[[trans-4-[[4-[[2-ethyl-5,7-dimethyl-3H-indolo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]methyl]-, ethanedisulfonate (2:1) (CA INDEX NAME)

CN 2

CNF 864171-77-7


CNF C20 H44 N6

Relative stereochemistry.

RU 864171-84-6 CAPLOS

CN Benzenamine, N-[[trans-4-[[4-methyl-1-piperazinyl]methyl]cyclohexyl]-4-[[2,5,7-trimethyl-3H-indolo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)


Relative stereochemistry.



RU 864171-85-7 CAPLOS

CN Cyclohexanecarboxamide, N-[[2-[[4-morpholinyl]ethyl]-4-[[4-[[2,5,7-trimethyl-3H-indolo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, trans- (CA INDEX NAME)


Relative stereochemistry.



RU 864171-86-8 CAPLOS

CN Cyclohexanecarboxamide, N-[[2-[[1-pyrrolidinyl]ethyl]-4-[[4-[[2,5,7-trimethyl-3H-indolo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.



CN 2

CNF 144-432-7


CNF C2 H2 O4



RU 864171-88-2 CAPLOS

CN 6-Morpholinethanamine, N-[[trans-4-[[4-[[2-ethyl-5,7-dimethyl-3H-indolo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)


Relative stereochemistry.



RU 864171-82-4 CAPLOS

CN Benzenamine, 4-[[2-ethyl-5,7-dimethyl-3H-indolo[4,5-b]pyridin-3-yl)methyl]-N-[[trans-4-[[4-[[4-morpholinyl]-1-piperidinyl]methyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RU 864171-84-6 CAPLOS

CN Benzenamine, N-[[trans-4-[[4-methyl-1-piperazinyl]methyl]cyclohexyl]-4-[[2,5,7-trimethyl-3H-indolo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)


Relative stereochemistry.



RU 864171-87-9 CAPLOS

CN 6-Morpholinethanamine, N-[[trans-4-[[4-[[2,5,7-trimethyl-3H-indolo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)


Relative stereochemistry.



RU 864171-83-0 CAPLOS

CN Methanone, 1-[[trans-4-[[4-[[2,5,7-trimethyl-3H-indolo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RU 864171-89-3 CAPLOS


CN Benzenamine, N-[[trans-4-[[4-[[4-morpholinyl]-1-piperidinyl]methyl]cyclohexyl]-4-[[2,5,7-trimethyl-3H-indolo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)

Relative stereochemistry.




864171-91-5 CAPLUS  
 CH Methanone, trans-4-[[4-[[2-ethyl-7-methyl-3H-indazole(4,5-b)pyridin-3-yl)methyl]phenyl]amino]cyclohexyl][4-methyl-3-piperidin-3-yl]- (CA INDEX NAME)

Relative stereochemistry.




864171-92-6 CAPLUS  
 CH Cyclohexanecarboxamide, 4-[[4-[[2-ethyl-7-methyl-3H-indazole(4,5-b)pyridin-3-yl)methyl]phenyl]amino]-N-[2-(1-pyrrolidinylethyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.




864171-93-7 CAPLUS  
 CH 4-Morpholinethanamine, N-[[trans-4-[[4-[[2-ethyl-7-methyl-3H-indazole(4,5-b)pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.




864172-10-1 CAPLUS  
 CH Cyclohexanone, 4-[[4-[[2-ethyl-5,7-dimethyl-3H-indazole(4,5-b)pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)



864172-11-4 CAPLUS  
 CH Cyclohexanecarboxamide, 4-[[4-[[2-(2-furanyl)-5,7-dimethyl-3H-indazole(4,5-b)pyridin-3-yl)methyl]phenyl]amino]-N-[2-(4-morpholinylethyl)-, trans- (CA INDEX NAME)


Relative stereochemistry.

Relative stereochemistry.




864171-95-9 CAPLUS  
 CH Methanone, trans-4-[[4-[[2,7-dimethyl-3H-indazole(4,5-b)pyridin-3-yl)methyl]phenyl]amino]cyclohexyl][4-methyl-3-piperidin-3-yl]- (CA INDEX NAME)

Relative stereochemistry.




864171-96-6 CAPLUS  
 CH Cyclohexanecarboxamide, 4-[[4-[[2,7-dimethyl-3H-indazole(4,5-b)pyridin-3-yl)methyl]phenyl]amino]-N-[2-(1-pyrrolidinylethyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.




864171-97-1 CAPLUS  
 CH 4-Morpholinethanamine, N-[[trans-4-[[4-[[2,7-dimethyl-3H-indazole(4,5-b)pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)




864172-22-5 CAPLUS  
 CH Methanone, trans-4-[[4-[[2-(2-furanyl)-5,7-dimethyl-3H-indazole(4,5-b)pyridin-3-yl)methyl]phenyl]amino]cyclohexyl][4-methyl-3-piperidin-3-yl]- (CA INDEX NAME)

Relative stereochemistry.



BN 864172-32-7 CAPLUS  
CN Benzenamine, 4-[[4-[[5-chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]-(4-methyl-1-piperazinyl)-, trans- (CA INDEX NAME)

Relative stereochemistry.




BN 864172-33-8 CAPLUS  
CN Cyclohexanecarboxamide, 4-[[4-[[5-chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-8-[2-(4-morpholinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.

BN 864172-38-3 CAPLUS  
CN Benzenamine, 4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[[4-[[4-methyl-1-piperazinyl)methyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



BN 864172-42-9 CAPLUS  
CN Benzenamine, 4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[[4-[[4-morpholinyl)methyl]cyclohexyl]-, ethanediolate (2:1) (CA INDEX NAME)

CN 3  
CNS 864172-43-8  
CNP C28 R39 MS O

Relative stereochemistry.




CN 2  
CNS 144-62-7  
CNP C2 R3 O4




BN 864172-43-0 CAPLUS  
CN Benzenamine, 4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[[4-[[4-(1-pyrrolidinyl)methyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.





BN 864172-34-9 CAPLUS  
CN Cyclohexanecarboxamide, 4-[[4-[[5-chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-8-[2-(1-pyrrolidinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




BN 864172-36-1 CAPLUS  
CN Cyclohexanecarboxylic acid, 4-[[4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester, cis- (CA INDEX NAME)

Relative stereochemistry.




BN 864172-45-2 CAPLUS  
CN Benzenamine, 4-[[4-[[4-methyl-1-piperazinyl)methyl]cyclohexyl]-4-[[2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)

Relative stereochemistry.



BN 864172-46-3 CAPLUS  
CN Cyclohexanecarboxamide, N-[2-(4-morpholinyl)ethyl]-4-[[4-[[2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, cis- (CA INDEX NAME)


Relative stereochemistry.



BN 864172-48-5 CAPLUS  
CN 6-Morpholinomethanamine, N-[[4-[[4-[[2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]methyl]-, ethanediolate (1:2) (CA INDEX NAME)

CN 864172-47-4  
CNF C29 H42 N6 O

Relative stereochemistry.



CN 2


CPS 144-62-7  
CNF C2 H2 O4



864172-49-6 CAPLUS

CN Methanone, 4-[(4-morpholinyl)-3-pyridinyl]-3-pyridinyl[1-cis-4-[[4-[[2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



864172-50-9 CAPLUS

CN Benzamide, N-[4-4-[[4-(4-morpholinyl)-3-pyridinyl]methyl]cyclohexyl]-4-[[2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl]- (CA INDEX NAME)


Relative stereochemistry.



864172-69-0 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[4-[[2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]amino]-, cis- (CA INDEX NAME)


Relative stereochemistry.



864172-71-4 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[4-[[2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]amino]-, trans- (CA INDEX NAME)


Relative stereochemistry.



864172-73-6 CAPLUS


CN Cyclohexanecarboxylic acid, 4-[[4-[[2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.



864172-74-7 CAPLUS


CN Cyclohexanecarboxylic acid, 4-[[4-[[2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]amino]-, trans- (CA INDEX NAME)



864172-52-1 CAPLUS

CN Benzamide, N-[4-4-[(4-morpholinyl)methyl]cyclohexyl]-4-[[2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl]- (CA INDEX NAME)


Relative stereochemistry.



864172-54-3 CAPLUS

CN 6-Pyridinemethanol, 1-[[4-4-[[4-[[2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



864172-62-3P

864172-69-0P

864172-71-4P

864172-73-6P

864172-75-5P

864172-76-3P

864172-77-5P

864172-82-7P

864172-83-7P

864172-84-7P

864172-85-7P

864172-86-7P

864172-87-7P

864172-88-7P

864172-89-7P

864172-90-7P

864172-91-7P

864172-92-7P

864172-93-7P

864172-94-7P

864172-95-7P

864172-96-7P

864172-97-7P

864172-98-7P

864172-99-7P

864172-100-7P

864172-101-7P

864172-102-7P

864172-103-7P

864172-104-7P

864172-105-7P

864172-106-7P

864172-107-7P

864172-108-7P

864172-109-7P

864172-110-7P

864172-111-7P

864172-112-7P

864172-113-7P

864172-114-7P

864172-115-7P

864172-116-7P

864172-117-7P

864172-118-7P

864172-119-7P

864172-120-7P

864172-121-7P

864172-122-7P

864172-123-7P

864172-124-7P

864172-125-7P

864172-126-7P

864172-127-7P

864172-128-7P

864172-129-7P

864172-130-7P

864172-131-7P

864172-132-7P

864172-133-7P

864172-134-7P

864172-135-7P

864172-136-7P

864172-137-7P

864172-138-7P

864172-139-7P

864172-140-7P

864172-141-7P

864172-142-7P

864172-143-7P

864172-144-7P

864172-145-7P

864172-146-7P

864172-147-7P

864172-148-7P

864172-149-7P

864172-150-7P

864172-151-7P

864172-152-7P

864172-153-7P

864172-154-7P

864172-155-7P

864172-156-7P

864172-157-7P

864172-158-7P

864172-159-7P

864172-160-7P

864172-161-7P

864172-162-7P

864172-163-7P

864172-164-7P

864172-165-7P

864172-166-7P

864172-167-7P

864172-168-7P

864172-169-7P

864172-170-7P

864172-171-7P

864172-172-7P

864172-173-7P

864172-174-7P

864172-175-7P

864172-176-7P

864172-177-7P

864172-178-7P

864172-179-7P

864172-180-7P

864172-181-7P

864172-182-7P

864172-183-7P

864172-184-7P

864172-185-7P

864172-186-7P

864172-187-7P

864172-188-7P

864172-189-7P

864172-190-7P

864172-191-7P

864172-192-7P

864172-193-7P

864172-194-7P

864172-195-7P

864172-196-7P

864172-197-7P

864172-198-7P

864172-199-7P

864172-200-7P

864172-201-7P

864172-202-7P

864172-203-7P

864172-204-7P

864172-205-7P

864172-206-7P

864172-207-7P

864172-208-7P

864172-209-7P

864172-210-7P

864172-211-7P

864172-212-7P

864172-213-7P

864172-214-7P

864172-215-7P

864172-216-7P

864172-217-7P

864172-218-7P

864172-219-7P

864172-220-7P

864172-221-7P

864172-222-7P

864172-223-7P

864172-224-7P

864172-225-7P

864172-226-7P

864172-227-7P

864172-228-7P

864172-229-7P

864172-230-7P

864172-231-7P

864172-232-7P

864172-233-7P

864172-234-7P

864172-235-7P

864172-236-7P

864172-237-7P

864172-238-7P

864172-239-7P

864172-240-7P

864172-241-7P

864172-242-7P

864172-243-7P

864172-244-7P

864172-245-7P

864172-246-7P

864172-247-7P

864172-248-7P

864172-249-7P

864172-250-7P

864172-251-7P

864172-252-7P

864172-253-7P

864172-254-7P

864172-255-7P

864172-256-7P

864172-257-7P

864172-258-7P

864172-259-





=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
23.74	227.30

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-3.40	-3.40

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 10:44:24 ON 08 JUL 2010